Clinical Trials Logo

Neurobehavioral Manifestations clinical trials

View clinical trials related to Neurobehavioral Manifestations.

Filter by:
  • Suspended  
  • Page 1

NCT ID: NCT05832255 Suspended - Clinical trials for Cognitive Dysfunction

An Investigation of Psilocybin on Behavioural and Cognitive Symptoms of Adults With Fragile X Syndrome

Start date: March 28, 2023
Phase: Phase 2
Study type: Interventional

Diverse symptomatology makes Fragile X Syndrome (FXS) difficult to treat, and currently there are no approved prevention or treatment methods for FXS. Current therapies, including pharmaceutical and behavioural interventions, offer a patchwork of solutions that have limited efficacy and high toxicity. The current study aims to examine psilocybin as a safe treatment alternative with the ability to improve markers of cognition, communication, mood, behavior as well as markers of neuroinflammation, serotonin levels in exosomes, and neuroplasticity at sub-hallucinogenic doses (microdosing). The overall objective of this study is to assess the feasibility of low-dose psilocybin as a therapeutic option for individuals living with FXS and to improve diagnostic parameters of FXS, as well as therapeutic responses with the use of biomarkers.

NCT ID: NCT02501434 Suspended - Clinical trials for Intracranial Aneurysm

Aneurysmal Subarachnoid Hemorrhage Trial RandOmizing Heparin

ASTROH
Start date: April 2016
Phase: Phase 2
Study type: Interventional

A Blind-adjudication Multi-center Phase II Randomized Clinical Trial of Continuous Low-dose Intravenous Heparin Therapy in Coiled Low-grade Aneurysmal Subarachnoid Hemorrhage Patients with Significant Hemorrhage Burden. - STUDY IS TEMPORARILY SUSPENDED WITH PLAN TO RESUME SOON. NO SAFETY CONCERNS